



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

*[Handwritten signature]*

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/718,986	11/21/2003	Mang Yu	21865-002001 / 6502	3664
20985	7590	09/27/2007		
FISH & RICHARDSON, PC P.O. BOX 1022 MINNEAPOLIS, MN 55440-1022			EXAMINER SAIDHA, TEKCHAND	
			ART UNIT	PAPER NUMBER
			1652	
			MAIL DATE	DELIVERY MODE
			09/27/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

**Office Action Summary**

Application No.

10/718,986

Applicant(s)

YU ET AL.

Examiner

Tekchand Saidha

Art Unit

1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 24 August 2007.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-3,5-10,12-14,16-20,22-24,31-34,47,50,54-58 and 61-98 is/are pending in the application.
- 4a) Of the above claim(s) 50,54-58 and 80-93 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-3,5-10,12-14,16-20,22-24,31-34,47,61-79 and 94-98 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date <u>7/31/07</u> . | 6) <input type="checkbox"/> Other: _____  |

Art Unit: 1652

**DETAILED ACTION**

1. Amendment filed 8/3/07 is acknowledged. Claims 1-3, 5-10, 12-14, 16-20, 22-24, 31-34, 47, 61-79 & 94-98 corresponding to the elected invention are under consideration

2. **Claims withdrawn** :

Claims 50, 54-58 & 80-93 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention.

3. Applicant's arguments filed 8/3/07 have been considered and not found to be persuasive. The reasons are discussed following the rejection(s).

4. Any objection or rejection of record which is not expressly repeated in this Office Action has been overcome by Applicant's response and withdrawn.

5. ***Written Description***

Claims 1-3, 5-10, 12-14, 16-20, 22-24, 31-34, 47, 61-79 & 94-98 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. These claims are directed to a genus of protein-based compositions comprising a compound (fusion protein) that comprises: at least one <sup>1</sup>therapeutic domain having extra cellular activity which may be catalytic or inhibitory and that can prevent infection of target cell; and one <sup>2</sup>anchoring domain which may be a binding domain (see specification pages 12-14 for the instantly stated definitions) and that can bind at or near the surface of the target cell; and pharmaceutical compositions thereof (claim 1). Dependent claims 2-3, 5-10, 12-14, 16-20, 22-

Art Unit: 1652

24, 31-34, 47, 61-79 & 94-98 identify target cell to be epithelial or endothelial, anchoring and therapeutic domains by the peptide names or sequence identifier number of one or the other domains, but lack the complete structure of the compound in any single claim nor specify having a defined function with respect to a specific pathogen or in preventing any specific infection.

The specification describes the composition comprising a compound consisting of an 'anchoring domain' and a 'therapeutic domain', wherein 'anchoring domain' is selected from the sequence of SEQ ID NO: 3, 4, 5 or 7, and wherein the 'therapeutic domain' is selected from SEQ ID NO: 8 or 9. The instantly exemplified species is not representative of the claimed genus.

The scope of genus includes many members with widely differing structural, chemical, and physicochemical properties including widely differing amino acid and/or nucleic acid sequences and biological functions. Furthermore, the genus is highly variable because a significant number of structural and biological differences between genus members exist.

The claims broadly recite the function 'therapeutic domain' to a peptide or protein having at least one extra-cellular enzyme or enzyme-inhibitor activity that can prevent the infection of a target cell by a pathogen by blocking entry into the target cell; and at least one 'anchoring domain' comprising a peptide or protein, wherein the anchoring domain can bind to a molecule on the surface of the target cell. The specification does not describe and define any structural features, nucleotide/protein/enzyme sequences, and biological functions that are commonly possessed by members of the genus

Art Unit: 1652

construct comprising the 'therapeutic domain' and members of the genus construct comprising 'anchoring domain'. The claims as written do not recite a particular structure to function relationship. The specification fails to provide a written description of representative nucleic acid and/or protein other than the anchoring domain. Claim 12, recites the partial structure of the construct wherein the composition comprising the anchoring domain consists of the amino acid sequence comprises the GAG-binding amino sequence of human platelet factor 4 of SEQ ID NO: 2, human interleukin 8 (SEQ ID NO: 3), human antithrombin III (SEQ ID NO: 4), human apoprotein E (SEQ ID NO: 5), human angio-associated migratory protein (SEQ ID NO: 6), or human amphiregulin (SEQ ID NO: 7). This is only a partial construct and does not include the structure of the 'therapeutic domain'. There is no description of any sequence that is substantially homologous thereof.

Similarly claim 22 depends upon claim 1, and broadly defines the 'therapeutic domain' to be an enzyme or an active portion thereof, wherein the active portion retains enzymatic activity and does not comprise the full length enzyme. The claim as written do not recite or encompass a particular structure to function relationship. Claims 33-34, specifies the structure of the 'therapeutic domain' to be a human sialidase is or is substantial homologous to NEU1, NEU2, NEU3 or NEU4; or a sequence that is or is substantially homologous to SEQ ID NO: 8 or SEQ ID NO: 9. There is no description of any sequence that is substantially homologous thereof.

The specification fails to provide a written description of representative composition other than one comprising the anchoring domain consisting of any one of the amino acid

Art Unit: 1652

sequence comprises the GAG-binding amino sequence of human platelet factor 4 of SEQ ID NO: 2, human interleukin 8 (SEQ ID NO: 3), human antithrombin III (SEQ ID NO: 4), human apoprotein E (SEQ ID NO: 5), human angio-associated migratory protein (SEQ ID NO: 6), or human amphiregulin (SEQ ID NO: 7) **and a 'therapeutic domain'** to be a human sialidase sequence of SEQ ID NO: 8 or SEQ ID NO: 9.

The Court of Appeals for the Federal Circuit has recently held that a "written description of an invention involving a chemical genus, like a description of a chemical species, 'requires a precise definition, such as be structure, formula [or] chemical name,' of the claimed subject matter sufficient to distinguish it from other materials." *University of California v. Eli Lilly and Co.*, 1997 U.S. App. LEXIS 18221, at \*23, quoting *Fiers v. Revel*, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993) (bracketed material in original). To fully describe a genus of genetic material, which is a chemical compound, applicants must (1) fully describe at least one species of the claimed genus sufficient to represent said genus whereby a skilled artisan, in view of the prior art, could predict the structure of other species encompassed by the claimed genus and (2) identify the common characteristics of the claimed molecules, e.g., structure, physical and/or chemical characteristics, functional characteristics when coupled with a known or disclosed correlation between function and structure, or a combination of these. Therefore, the instant claims are not adequately described.

In view of the above consideration, Applicants have failed to sufficiently describe the claimed invention, in such full, clear, concise, and exact terms that a skilled artisan

Art Unit: 1652

would recognize Applicants were in possession of the claimed protein composition comprising any 'therapeutic domain' and any 'anchoring domain'.

Applicants' arguments:

Citing *In re Wertheim*, 541 F.2d 257, 262, 191 USPQ 90, 96 (CCPA 1976), Applicants argue that the manner in which the specification meets the [written description] requirement is not material; it may be met by either an express or an implicit disclosure.

Discussing the Federal Circuit court decision on written description requirement of the first paragraph of 112 to claims in the field of biotechnology [See *University of California v. Eli and Co.*, 19 F.3d 1559, 43 USPQ2d 1398, 1406 (Fed. Cir. 1997)], Applicants explain the court as follows: '

In claims involving chemical materials, generic formulae usually indicate with specificity what the generic claims encompass. One skilled in the art can distinguish such a formula from others and can identify many of the species that the claims encompass.

A specification must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention, i.e., whatever is now claimed. *Vas-Cath, Inc. v. Mahurkar*, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991). A written description requirement issue generally involves the question of whether the subject matter of a claim is supported by or conforms to the disclosure of an application as filed. The test for sufficiency of support in a patent application is whether the disclosure of the application relied upon "reasonably conveys to the artisan that the inventor had

Art Unit: 1652

possession at that time of the later claimed subject matter." *Ralston Purina Co. v. Far- Mar-Co., Inc.*, 772 F.2d 1570, 1575, 227 USPQ 177, 179 (Fed. Cir. 1985) (quoting *In re Kaslow*, 707 F.2d 1366, 1375, 217 USPQ 1089, 1096 (Fed. Cir. 1983)) (see also, MPEP 2163.02).

An objective standard for determining compliance with the written description requirement is "does the description clearly allow persons of skill in the art to recognize that he or she invented what is, claimed." *In re Gosteli*, 872 F.2d 1008, 1012, 10 USPQ.2d 1614, 1618 (Fed. Cir. 1989).

Applicants argue that 'This standard is met in the instant case'. The combination of the disclosure in the specification, including the disclosure of several examples of known compounds that can function as therapeutic and anchoring domains in the claimed compositions, exemplification of the preparation of specific protein-based compositions containing the two domains using standard methods known to those of skill in the art, assays to measure the activity of each of the domains and of pathogen infectivity as known to those of skill in the art, and the extensive knowledge of those of skill in the art regarding the component domains and the pathways of pathogenic infection, evidence possession by Applicant, at the time of filing, of the generic concept of preventing or treating pathogenic infection of a target cell based on an inhibitory activity that is directed to the surface of the target cell.

Applicants' arguments are considered but not found to be persuasive, because the exemplified protein-based composition comprising a compound consisting of an 'anchoring domain' and a 'therapeutic domain', wherein 'anchoring domain' is selected



Art Unit: 1652

from the sequence of SEQ ID NO: 3, 4, 5 or 7, and wherein the 'therapeutic domain' is selected from SEQ ID NO: 8 or 9 (the disclosed species), is not representative of the claimed genus. This is because the "written description of an invention involving a chemical genus, like a description of a chemical species, 'requires a precise definition, such as be structure, formula [or] chemical name,' of the claimed subject matter sufficient to distinguish it from other materials." University of California v. Eli Lilly and Co., 1997 U.S. App. LEXIS 18221, at \*23, quoting Fiers v. Revel, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993) (bracketed material in original). Such a structure and/or function is not defined by the claim, and one skilled in the art cannot reasonably identify all such compositions comprising a compound consisting of an 'anchoring domain' and a 'therapeutic domain' from any source, where no structure is apparent. The written description rejection is therefore maintained.

6. **Enablement Rejection**

Claims 1-3, 5-10, 12-14, 16-20, 22-24, 31-34, 47, 61-79 & 94-98 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the composition comprising a compound consisting of an 'anchoring domain' and a 'therapeutic domain', wherein 'anchoring domain' is selected from the sequence of SEQ ID NO: 3, 4 5 or 7, and wherein the 'therapeutic domain' is selected from SEQ ID NO: 8 or 9, does not reasonably provide enablement for any composition comprising compounds consisting of an 'anchoring domain' and a 'therapeutic domain' of undetermined structure and function be used for preventing pathogenic infection.

Art Unit: 1652

The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

The scope of the claims does not commensurate with the enablement provided by the disclosure with regard to the extremely large number of compounds (fusion protein constructs) broadly encompassed by the claims.

The nature of the invention and the breadth of the claims: The claimed invention is drawn to claims directed to a protein-based compositions comprising a compound (fusion protein) that comprises: at least one <sup>1</sup>therapeutic domain having extra cellular activity which may be catalytic or inhibitory and that can prevent infection of target cell; and one <sup>2</sup>anchoring domain which may be a binding domain (see specification pages 12-14 for the instantly stated definitions) and that can bind at or near the surface of the target cell; and pharmaceutical compositions thereof (claim 1). Dependent claims 2-3, 5-10, 12-14, 16-20, 22-24, 31-34, 47, 61-79 & 94-98 identify target cell to be epithelial or endothelial, anchoring and therapeutic domains by the peptide names or sequence identifier number of one or the other domains, but lack the complete structure of the compound in any single claim nor specify having a defined function with respect to a specific pathogen or in preventing any specific infection. The instant claims encompass in vivo therapy as evidenced by the claims to a pharmaceutical composition. The claims are also drawn to variants, fragments, sequences which are substantially identical and/or active fragments thereof of the 2 domains included in the fusion protein.

Art Unit: 1652

The state of the prior art and the level of predictability in the art:

The art teaches that the efficacy of the therapeutics is dependent upon factors such as solubility of the drug, bioavailability at the target site, attainment of effective plasma concentration, solubility in tissues, biotransformation, toxicity, proteolytic degradation, immunological inactivation, rate of excretion or clearance (half-life), deactivation by the liver, hydrolysis in serum, and binding to plasma protein, see Benet et al., pp. 3-32, in Pharmacological Basis of Therapeutics, 8th ed., 1990, page 3, first paragraph; page 5, second column, last partial paragraph, first two sentences; page 10, the paragraph bridging columns 1 and 2; page 18, the paragraph bridging columns 1 and 2; page 20, last full paragraph; and the paragraph bridging pages 20 and 21.

The amount of direction provided and the existence of working examples: Given "the teachings of unpredictability regarding the efficacy of fusion molecules for in vivo therapy, detailed teachings are required to be present in the specification sufficient to overcome the teachings of unpredictability which are found in the art. Such teachings are absent. While the specification makes the general statement that the fusion proteins of the claimed invention are useful for preventing infection in a target cell in vitro and in vivo, there is no guidance as to how to accomplish this in vivo. There appears to not even one clear working example of preventing infection in a target cell with a fusion protein.

A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one

Art Unit: 1652

skilled in the art how to make and/or use the full scope of the claimed inventions without undue experimentation. In re Wright, 27 USPQ2d 1510 (CAFC). The disclosure does not demonstrate sufficient evidence to support Applicants' claim to functional pro-apoptosis-modifying fusion proteins capable of binding a target cell in vivo. All of the factors considered in the sections above, underscores the criticality of providing working examples in the specification for an unpredictable art such as preventing infection in a target cell with a fusion protein in vivo.

Quantity of experimentation needed to make or use the invention based on the content of the disclosure: In view of the Wands factors considered above, one of ordinary skill in the art would conclude that preventing infection in a target cell using a fusion protein in vivo would require undue experimentation in order to use the invention as claimed by the Applicants.

Thus, applicants have not provided sufficient guidance to enable one of ordinary skill in the art to make and use the claimed invention in a manner reasonably correlated with the scope of the claims. The scope of the claims must bear a reasonable correlation with the scope of enablement (In re Fisher, 166 USPQ 19 24 (CCPA 1970)). Without sufficient guidance, determination of exact nature of the compound (fusion protein) that comprises: at least one <sup>1</sup>therapeutic domain having extra cellular activity which may be catalytic or inhibitory and that can prevent infection of target cell; and one <sup>2</sup>anchoring domain which may be a binding domain is unpredictable and the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue. See In re Wands 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir, 1988).

Art Unit: 1652

Applicants' arguments:

Applicants cite numerous case laws and argue that - Enablement is a legal determination that assesses whether a specification teaches one of skill in the art to make and use what is claimed. Enablement is not precluded even if some experimentation is necessary, as long as the amount of experimentation is not undue. *Atlas Powder Co. v. E. I. Du Pont De Nemours Co.*, 750 224 USPQ 409, 3 (Fed. Cir. 1984); *W. L. Gore and Associates v. Inc*, 721 220 USPQ 303,315 (Fed. Cir. 1983).

Nothing more than objective enablement is required, and therefore it is irrelevant whether this teaching is provided through broad terminology or illustrative examples. In *re Marzocchi* 439 220, 223, 169 USPQ 367, 369 (CCPA 1971). An analysis of whether the rejected claims are supported by an enabling disclosure requires a determination of whether that disclosure contained sufficient information regarding the subject matter of the claims to teach one of skill in the art how to make and use what is claimed. "[I]t is not a function of the claims to specifically exclude either possible inoperative substances or ineffective reacting proportions." In *Application of Dinh-Nguyen*, 492 F.2d 865 at 858-9 181 USPQ 46 (CCPA (1974)). Thus, a claim is not too broad because it does not explicitly exclude every conceivable unworkable application of the method, providing it enables one of skill in the art to practice what is claimed in its workable applications.

Notably, to establish a *prima facie* case of lack of enablement, the Examiner has the initial burden to establish a reasonable basis to question the enablement provided for what is claimed. In *re Wright*, 999 1557, 1561-62, 27 1510, 1513 (Fed. Cir. 1993). (Examiner must provide a reasonable explanation as

Art Unit: 1652

to why the scope of protection provided by a claim is not adequately enabled by the disclosure). See also Morehouse, 545 162, 192 USPQ 29 (CCPA 1976). The threshold step in resolving this issue is to determine whether the Examiner has met this burden of proof by advancing acceptable reasoning inconsistent with enablement.

The most relevant arguments put forward by the Applicants are:

1. The examiner is rejecting claims for lack of enablement of a use of the instant compositions and pharmaceutical compositions.

This is not the case - Examiner rejection is for product claims at large. The claims to pharmaceutical compositions by definition involves an implied use aspect which has been addressed in the rejection. The claims have not been treated as claims for lack of enablement of a use of the instant composition. Applicants are requested to revisit the enablement rejections.

2. Applicants argue that contrary to Examiner's assertion, the specification provides the common structural and functional features.

In response, it is noted that common structural and functional features are not reflected in the claims.

3. The specification teaches that the therapeutic domain can act in a variety of ways, including: (1) binding to a target cell receptor that is necessary for binding of the pathogen to the target cell; (2) binding to a molecule or epitope on a pathogen to prevent its interaction with a target cell that is necessary for infection; (3) degrading a molecule or epitope on the pathogen or target cell to prevent an interaction necessary

Art Unit: 1652

for infection; or (4) inhibiting an activity of the pathogen or target cell that is necessary for infection. The specification further teaches that the therapeutic domain can have a catalytic activity that can digest a molecule or epitope of the pathogen or target cell that is required for target cell-pathogen binding, and block subsequent entry of the pathogen into the target cell (page 20, lines 5-9).

Applicants' arguments are considered but not found to be persuasive because such a generalized teaching is useful, however, does not enable a skilled artisan to practice the entire scope of the invention without undue experimentation as well as high level of unpredictability. Further, it is important to clear-cut guideline for making compounds comprising an anchoring and a therapeutic domain wherein the domains have a defined structure and a function, in order that the compounds produced can be employed in a composition.

Applicants address the various Wand factors and argue that the specification teach by way of examples further teaches the construction of proteins containing each of the exemplified therapeutic and anchoring domains (e.g., page 19, lines 5-16 and page 21, line 23 to page 22, line 2). At page 11, line 13 to page 12, line 3, the specification teaches how methods known to those of skill in the art can be used to make the protein-based compositions as claimed, and tested for their activity based on standard assays, depending on the class of protein (e.g., sialidase or protease inhibitor). The Examples, discussed below, further describe how an exemplary enzyme inhibitor, aprotinin, an exemplary enzyme, a sialidase, and an exemplary anchoring domain, a GAG-binding domain, can be expressed, purified, tested

Art Unit: 1652

for their activity, incorporated into a protein-based composition containing.

Specific examples on page 19, as pointed out in the enablement rejection point to specific structure by way of SEQ ID Nos. XYZ, and Applicants are enabled for these specific constructs. However, these constructs have not been disclosed or guidance provided in the specification to extrapolate these specific constructs to include composition comprising a compound consisting of an 'anchoring domain' and a 'therapeutic domain' from any source and no clearly defined structure.

The rejection is maintained for all the above reasons.

7. **Pharmaceutical composition**

Claims 47, 72-73 & 77-79 rejected under 35 U.S.C. § 112, first paragraph, as the disclosure is enabling only for claims limited to the composition comprising a compound consisting of an 'anchoring domain' and a 'therapeutic domain', wherein 'anchoring domain' is selected from the sequence of SEQ ID NO: 3, 4 5 or 7, and wherein the 'therapeutic domain' is selected from SEQ ID NO: 8 or 9.

Factors to be considered in determining whether undue experimentation is required, are summarized in *re Wands* 858 F.2d 731, 8 USPQ2d 1400 (Fed. Cir, 1988) [ *Ex parte* Forman [230 USPQ 546 (Bd. Pat. App. & Int. 1986)]]. The Wands factors are: (a) the quantity of experimentation necessary, (b) the amount of direction or guidance presented, (c) the presence or absence of working example, (d) the nature of the invention, (e) the state of the prior art, (f) the relative skill of those in the art, (g) the predictability or unpredictability of the art, and (h) the breadth of the claim.



Art Unit: 1652

It is neither taught nor any data is provided for using the specific fusion protein construct in pharmaceutical compositions for the treatment and or prevention of any of the diseases or disorders or infections. There is no evidence presented that specific fusion protein construct(??) is associated with any of the known diseases or disorders or infections or can be treated or prevented by administering the specific fusion protein construct(??). Without such a data or evidence, claims to pharmaceutical composition comprising specific fusion protein construct(??), would amount to a composition or potential drug for treatment for any disorder or disease or infection, which is not enabled. Given the lack of direction or guidance and the nature of the invention, obtaining such a composition for one of skill in the art would be highly unpredictable. This is because the specific fusion protein construct(??) when associated with a particular disease or disorder or infection would be expressed differentially. Manipulating or controlling these levels depends upon the disease or disorder or infection, and may not always be controlled by supplementing with such a specific fusion protein construct(??) composition. Further, no guidance is provided, pertaining to the fate of the administered specific fusion protein construct(??) *in vivo*.

Since it is not routine in the art to engage in *de novo* experimentation to prepare numerous compositions where the expectation "of success is unpredictable", the skilled artisan would require additional guidance, specific to individual disorder or disease or infection, in order to make and use pharmaceutical compositions in a manner reasonably commensurate with the scope of the claims. Without such

Art Unit: 1652

guidance, the experimentation left to those skilled in the art is undue.

8. **Claim Rejections - 35 USC § 112** (second paragraph)

Claims 8-10, 12, 34, 61-64 & 94, are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 8, 12, 34, 61 & 94 recite the phrase 'substantially homologous to'. The claims are indefinite because the metes and bounds of the claims are unclear.

Claims 9-10 & 62-64 are included in the rejection for failing to correct the defect present in the base claim(s).

9. **Claim Rejections - 35 USC § 102**

The following is a quotation of the appropriate paragraphs of 35 U.S.C. § 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

Claims 1-4, 47, 65, 70 are rejected under 35 U.S.C. 102(e) as being anticipated by Youle et al. (USP 6,737,511, 8/16/1999).

The instant claims are broadly drawn to a protein-based composition comprising a compound (fusion protein) that comprises: at least one <sup>1</sup>therapeutic domain having extra cellular activity which may be catalytic or inhibitory and that can prevent infection of target cell; and one <sup>2</sup>anchoring domain which may be a binding domain (see specification pages 12-14 for the instantly stated definitions) and that can bind at or near the

Art Unit: 1652

surface of the target cell; and pharmaceutical compositions thereof.

Youle et al. teach apoptosis-inhibiting fusion protein composition comprising: (1) first domain or an inhibitory domain, (2) a second domain capable of targeting the fusion protein to the target cell which is the similar in function as the anchoring or binding domain of the claimed construct and (3) a linker connecting the first and the second domains (see claims 1-12, abstract, examples, and the entire patent). All claim limitations being taught the reference is anticipatory.

Applicants' arguments:

Applicants argue that Youle et al. does not disclose any protein-based composition containing an enzyme or enzyme inhibitor activity that prevents infection of a target cell by an external agent, such as a pathogen. The "therapeutic" or "inhibitory" domain disclosed in Youle et al. modifies an endogenous signal (apoptosis) in the target cell; it is not a domain having an activity that prevents infection of a target cell by a pathogen. In fact, Youle et al. discloses that for the domain to modify apoptosis, the protein-based composition must be capable of being translocated across the membrane and internalized into the target cell. Youle et al. does not disclose a protein having an extra cellular inhibitory activity of any kind, much less an activity that prevents infection of a target cell by a pathogen. As the instant claims specify, and as the specification exemplifies, the protein-based compounds of the compositions claimed herein contain an extra-cellular activity that prevents pathogenic infection, i.e., it is an activity that is based at the target cell surface or acts on the pathogen before it infects the target cell, such as an activity that

Art Unit: 1652

cleaves a target cell molecule at the cell surface or otherwise modifies the pathogen or the pathway for pathogen infectivity before it enters the cell. Since anticipation requires that a reference disclose every element as claimed, Youle et al, which does not disclose a protein-based composition in which one of the protein or peptide domains has an extra cellular enzyme or enzyme inhibitor activity that can prevent infection of a target cell by a pathogen, does not anticipate the claims.

Applicants' arguments are considered but not found to be persuasive because Youle et al. teach apoptosis-inhibiting fusion protein composition comprising: (1) first domain or an inhibitory domain, (2) a second domain capable of targeting the fusion protein to the target cell which is the similar in function as the anchoring or binding domain of the claimed construct and (3) a linker connecting the first and the second domains (see claims 1-12, abstract, examples, and the entire patent). Since there is no evidence to the contrary, the compound prepared by Youle inherently has extra-cellular activity that prevents pathogenic infection. The claims as written are so broad as to be anticipated by the reference.

10. **Double Patenting**

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground

Art Unit: 1652

provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-3, 5-10, 12-14, 16-20, 22-24, 31-34, 47, 61-79 & 94-98 are provisionally rejected under the judicially created doctrine of double patenting over claims 141-147, 149, 151, 162-169 & 171 of copending Application No. 10/939,262. This is a provisional double patenting rejection since the conflicting claims have not yet been patented.

The subject matter claimed in the instant application is fully disclosed in the referenced copending application and would be covered by any patent granted on that copending application since the referenced copending application and the instant application are claiming common subject matter, as follows:

The instant claims are directed to a genus of protein-based compositions comprising a compound (fusion protein) that comprises: at least one <sup>1</sup>therapeutic domain having extra cellular activity which may be catalytic or inhibitory and that can prevent infection of target cell; and one <sup>2</sup>anchoring domain which may be a binding domain (see specification pages 12-14 for the instantly stated definitions) and that can bind at or near the surface of the target cell. The claims of the copending application are drawn to a fusion protein comprising catalytic domain of sialidase of SEQ ID NO: 16 and an anchoring domain. The instant claims are broader genus composition claims comprising a therapeutic domain (or catalytic domain) and an anchoring domain (or binding domain) and comprises the species claims in the copending application. Since a species anticipates the genus [& genus obviates a species], the copending species

Art Unit: 1652

claims of U.S. Serial No. 10/939,262 anticipate the instantly claimed generic claims.

11 No claim is allowed.

12. Allowable subject matter-

Claims drawn to a composition comprising a compound consisting of an 'anchoring domain' and a 'therapeutic domain', wherein 'anchoring domain' is selected from the sequence of SEQ ID NO: 3, 4 5 or 7, and wherein the 'therapeutic domain' is selected from SEQ ID NO: 8 or 9, will be in a better condition for allowance.


13. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

14. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tekchand Saidha whose telephone number is (571) 272 0940. The examiner can normally be reached on 8.30 am - 5.00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapu Achutamurthy can be reached on (571) 272 0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Tekchand Saidha

Primary Examiner, Art Unit 1652

Recombinant Enzymes, 02A65 Remsen Bld.

400 Dulany Street, Alexandria, VA 22314

Telephone: (571) 272-0940

September 24, 2007